Tan Fang, Kong Chang-Suk
Department of Bioscience, Silla University, Busan 46958, Republic of Korea.
Department of Food Science and Nutrition, Silla University, Busan 46958, Republic of Korea.
Biomolecules. 2025 Mar 1;15(3):358. doi: 10.3390/biom15030358.
HFY11 (LP-HFY11) is a newly discovered microbial strain. This study was the first to investigate the preventive effect of LP-HFY11 on compound diphenoxylate induced constipation in mice by measuring intestinal contents, serum, and small intestinal tissue indexes. In mice suffering from constipation, LP-HFY11 could prevent the reduction in fecal weight, particle count, and water content. The constipated mice that ingested a high LP-HFY11 dose (LP-HFY11H) expelled the first black stool faster than the model group and the drug lactulose-treated group, but they were slower than the normal group. Furthermore, the small intestine in the LP-HFY11H group had a greater propulsion rate of activated charcoal than that in the model and lactulose groups, but the propulsion rate was still lower than that in the normal group. According to hematoxylin-eosin (H&E) staining, LP-HFY11H was more effective than lactulose at reducing intestinal villi breaking and constipation-induced harm to the small intestine. Simultaneously, compared with the model group, the LP-HFY11H group had markedly increased serum levels of motilin (MTL), endothelin-1 (ET-1), vasoactive intestinal peptide (VIP), and acetylcholinesterase (AchE). Transient receptor potential vanilloid 1 (TRPV1) expression was only higher than in the normal group, but the mRNA expression of c-Kit, stem cell factor (SCF), and glial cell line-derived neurotrophic factor (GDNF) was all higher in the small intestine in the LP-HFY11H group than in the model and lactulose groups, according to the results of quantitative polymerase chain reaction (qPCR) experiments. Analysis of microbial mRNA in the small intestinal contents of the constipated mice further validated the capacity of LP-HFY11 to decrease the abundance of and increase the abundance of , , and . This revealed that LP-HFY11, which produced better results than the drug lactulose, can control the gut microbiota of constipated mice and successfully cure constipation. LP-HFY11 has the potential to be used as a probiotic in the treatment of constipation. It has good application prospects in the food industry and biopharma.
HFY11（LP - HFY11）是一种新发现的微生物菌株。本研究首次通过测量肠道内容物、血清和小肠组织指标，研究LP - HFY11对复方地芬诺酯诱导的小鼠便秘的预防作用。在便秘小鼠中，LP - HFY11可防止粪便重量、颗粒计数和水分含量的减少。摄入高剂量LP - HFY11（LP - HFY11H）的便秘小鼠排出第一粒黑便的时间比模型组和药物乳果糖治疗组更快，但比正常组慢。此外，LP - HFY11H组小肠中活性炭的推进率高于模型组和乳果糖组，但推进率仍低于正常组。根据苏木精 - 伊红（H&E）染色，LP - HFY11H在减少肠绒毛断裂和便秘引起的小肠损伤方面比乳果糖更有效。同时，与模型组相比，LP - HFY11H组血清胃动素（MTL）、内皮素 - 1（ET - 1）、血管活性肠肽（VIP）和乙酰胆碱酯酶（AchE）水平明显升高。根据定量聚合酶链反应（qPCR）实验结果，瞬时受体电位香草酸亚型1（TRPV1）表达仅高于正常组，但LP - HFY11H组小肠中c - Kit、干细胞因子（SCF）和胶质细胞源性神经营养因子（GDNF）的mRNA表达均高于模型组和乳果糖组。对便秘小鼠小肠内容物中微生物mRNA的分析进一步证实了LP - HFY11降低 丰度并增加 、 和 丰度的能力。这表明LP - HFY11比药物乳果糖产生更好的效果，可控制便秘小鼠的肠道微生物群并成功治愈便秘。LP - HFY11有潜力作为治疗便秘的益生菌使用。它在食品工业和生物制药领域具有良好的应用前景。
